Apothecon et al.; Withdrawal of Approval of 103 New Drug Applications and 35 Abbreviated New Drug Applications; Correction, 64951 [2011-26967]
Download as PDF
<![CDATA[
Federal Register / Vol. 76, No. 202 / Wednesday, October 19, 2011 / Notices
Dated: October 14, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011–27020 Filed 10–18–11; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2011–N–0002]
Cellular, Tissue and Gene Therapies
Advisory Committee; Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
emcdonald on DSK5VPTVN1PROD with NOTICES
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: Cellular, Tissue
and Gene Therapies Advisory
Committee.
General Function of the Committee:
To provide advice and
recommendations to the Agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on November 17, 2011, from 8:30
a.m. to 5 p.m.
Location: Hilton Washington, DC/
Silver Spring, 8727 Colesville Rd.,
Silver Spring, MD 20910, 301–589–
5200. For those unable to attend in
person, the meeting will also be
available by Web cast. On September 22,
2011, the link for the Web cast is
available at https://fda.yorkcast.com/
webcast/Viewer/?peid=041ef376b14
f4599be568b1b2893e85d1d.
Contact Person: Gail Dapolito or
Sheryl Clark, Center for Biologics
Evaluation and Research (HFM–71),
Food and Drug Administration, 1401
Rockville Pike, Rockville, MD 20852,
301–827–0314, or FDA Advisory
Committee Information Line, 1–800–
741–8138 (301–443–0572 in the
Washington, DC, area), and follow the
prompts to the desired center or product
area. Please call the Information Line for
up-to-date information on this meeting.
A notice in the Federal Register about
last minute modifications that impact a
previously announced advisory
committee meeting cannot always be
published quickly enough to provide
timely notice. Therefore, you should
always check the Agency’s Web site and
call the appropriate advisory committee
hot line/phone line to learn about
possible modifications before coming to
the meeting.
VerDate Mar<15>2010
16:34 Oct 18, 2011
Jkt 226001
Agenda: On November 17, 2011,the
committee will discuss Apligraf (Oral),
Organogenesis, Inc., BLA 125400, for
the treatment of surgically created
gingival and alveolar mucosal surface
defects in adults.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before November 9, 2011.
Oral presentations from the public will
be scheduled between approximately
11:35 p.m. and 12:35 p.m. Those
individuals interested in making formal
oral presentations should notify the
contact person and submit a brief
statement of the general nature of the
evidence or arguments they wish to
present, the names and addresses of
proposed participants, and an
indication of the approximate time
requested to make their presentation on
or before November 1, 2011. Time
allotted for each presentation may be
limited. If the number of registrants
requesting to speak is greater than can
be reasonably accommodated during the
scheduled open public hearing session,
FDA may conduct a lottery to determine
the speakers for the scheduled open
public hearing session. The contact
person will notify interested persons
regarding their request to speak by
November 2, 2011.
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Gail Dapolito
at least 7 days in advance of the
meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/Advisory
Committees/AboutAdvisoryCommittees/
PO 00000
Frm 00060
Fmt 4703
Sfmt 9990
64951
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: October 12, 2011.
Jill Hartzler Warner,
Acting Associate Commissioner for Special
Medical Programs.
[FR Doc. 2011–27038 Filed 10–18–11; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2009–N–0026]
Apothecon et al.; Withdrawal of
Approval of 103 New Drug
Applications and 35 Abbreviated New
Drug Applications; Correction
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice; correction.
The Food and Drug
Administration (FDA) is correcting a
notice that appeared in the Federal
Register of February 11, 2009 (74 FR
6896). The document withdrew
approval of 103 new drug applications
(NDAs) and 35 abbreviated new drug
applications (ANDAs) from multiple
applicants. The document inadvertently
withdrew approval of NDA 50–435 for
GEOCILLIN (carbenicillin indanyl
sodium) Tablets held by Pfizer, Inc., 235
East 42d St., New York, NY 10017. FDA
confirms that approval of NDA 50–435
is still in effect.
SUMMARY:
FOR FURTHER INFORMATION CONTACT:
Florine Purdie, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, rm. 6366,
Silver Spring, MD 20993–0002, 301–
796–3601.
In FR Doc.
E9–2901, appearing on page 6896, in the
Federal Register of Wednesday,
February 11, 2009, the following
correction is made:
1. On page 6900, in the table, the
entry for NDA 50–435 is removed.
SUPPLEMENTARY INFORMATION:
Dated: September 30, 2011.
Janet Woodcock,
Director, Center for Drug Evaluation and
Research.
[FR Doc. 2011–26967 Filed 10–18–11; 8:45 am]
BILLING CODE 4160–01–P
E:\FR\FM\19OCN1.SGM
19OCN1
]]>Agencies
[Federal Register Volume 76, Number 202 (Wednesday, October 19, 2011)]
[Notices]
[Page 64951]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-26967]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2009-N-0026]
Apothecon et al.; Withdrawal of Approval of 103 New Drug
Applications and 35 Abbreviated New Drug Applications; Correction
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice; correction.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is correcting a notice
that appeared in the Federal Register of February 11, 2009 (74 FR
6896). The document withdrew approval of 103 new drug applications
(NDAs) and 35 abbreviated new drug applications (ANDAs) from multiple
applicants. The document inadvertently withdrew approval of NDA 50-435
for GEOCILLIN (carbenicillin indanyl sodium) Tablets held by Pfizer,
Inc., 235 East 42d St., New York, NY 10017. FDA confirms that approval
of NDA 50-435 is still in effect.
FOR FURTHER INFORMATION CONTACT: Florine Purdie, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, rm. 6366, Silver Spring, MD 20993-0002, 301-
796-3601.
SUPPLEMENTARY INFORMATION: In FR Doc. E9-2901, appearing on page 6896,
in the Federal Register of Wednesday, February 11, 2009, the following
correction is made:
1. On page 6900, in the table, the entry for NDA 50-435 is removed.
Dated: September 30, 2011.
Janet Woodcock,
Director, Center for Drug Evaluation and Research.
[FR Doc. 2011-26967 Filed 10-18-11; 8:45 am]
BILLING CODE 4160-01-P
